Log In
BCIQ
Print this Print this
 

dexrazoxane (Cardioxane)

  Manage Alerts
Collapse Summary General Information
Company Clinigen Group plc
DescriptionIron chelator
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard Indication Cardiovascular (unspecified)
Indication DetailsPrevent cardiotoxicity of anthracycline chemotherapy in patients with advanced, metastatic breast cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$33.0M

$33.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/04/2013

$33.0M

$33.0M

0

Get a free BioCentury trial today